IDEXX Laboratories, Inc. $IDXX Shares Sold by The Manufacturers Life Insurance Company

Key Points

• The Manufacturers Life Insurance Company reduced its IDEXX Laboratories stake by 25.3% in the first quarter, selling 14,464 shares and retaining 42,655 shares valued at approximately $23.97 million. Institutional investors collectively own 87.84% of the company.
• IDEXX reported a quarterly earnings beat, with EPS of $3.47 versus the $3.41 consensus estimate and revenue of $1.14 billion, up 14.3% year over year. The company provided fiscal 2026 EPS guidance of $14.45 to $14.90.
• Analyst sentiment remains positive but cautious: the stock has a “Moderate Buy” consensus rating and a $749 average price target, while shares recently traded near $559.07.

The Manufacturers Life Insurance Company lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 25.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 42,655 shares of the company's stock after selling 14,464 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.05% of IDEXX Laboratories worth $23,967,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. SHP Wealth Management acquired a new stake in IDEXX Laboratories during the 4th quarter worth approximately $26,000. Virtus Advisers LLC acquired a new position in shares of IDEXX Laboratories in the third quarter valued at approximately $26,000. WealthCollab LLC acquired a new position in shares of IDEXX Laboratories in the second quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of IDEXX Laboratories during the third quarter worth approximately $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company's stock worth $37,000 after purchasing an additional 20 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Trading Up 0.0%

Shares of IDXX stock opened at $559.07 on Friday. The business's fifty day moving average price is $557.36 and its 200 day moving average price is $590.40. The firm has a market capitalization of $44.10 billion, a PE ratio of 41.17, a P/E/G ratio of 3.06 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, beating analysts' consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the company earned $2.91 earnings per share. IDEXX Laboratories's quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of analyst reports. Weiss Ratings upgraded shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Wednesday. Citigroup assumed coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a "neutral" rating and a $650.00 target price for the company. UBS Group lowered their target price on shares of IDEXX Laboratories from $640.00 to $620.00 and set a "neutral" rating on the stock in a report on Monday, July 27th. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $749.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source